Simultaneous genotyping and RAS-calling with the *Sentosa*® SQ HCV Genotyping Assay
Delivers genotyping & RAS identification accuracy in a single, efficient workflow

Reliable, automated solution – full workflow automation combined with built-in controls give you confidence in your results

Speeds time to next steps – simultaneously analyze genotyping and RAS-calling with minimal hands-on-time using our automated solution

Expert assay design – multiplexed sequencing design targets key regions indicated in AASLD guidelines including genotypes 1 through 6 as well as 70 subtypes enabling discovery of potential new relationships between subtypes and novel therapeutics

Overview

Prior to 2011, therapies for treatment of the Hepatitis C Virus (HCV) focused on interferon-based therapy. In 2011 it was found that the genotype of the virus is clinically important, both in response of interferon-based therapy and to other potential therapies. Current AASLD guidelines recommend specific combination therapies for each genotype as well as subtypes 1a & 1b1. The introduction of these targeted therapies has reduced adverse effects and increased cure rates from 45% to 93% in genotype 1, for example2. Further research to develop additional genotype-specific targeted therapies will continue to improve outcomes for this disease. This research makes accurate determination of HCV genotype critical in the development of novel therapies for HCV.

Accurate HCV Genotyping and RAS analysis

The Sentosa® SQ HCV Genotyping Assay uses next-generation sequencing technology to deliver accuracy in the detection of Hepatitis C Virus genotypes 1-6, and their associated subtypes as well as resistance-associated substitutions (RASs). Compared with traditional methods for HCV genotyping such as line-probe assays (LiPA), this next-generation sequencing-based assay eliminates genotyping errors (Table 1) while simultaneously delivering additional information about RASs found in the sample. As shown in an external study comparing HCV genotyping results using NGS, Sanger Sequencing, and LiPA, the Sentosa SQ HCV Genotyping assay delivered 100% accurate genotyping assignment while the LiPA approach yielded 11% inaccurate genotyping assignments, potentially leading to incorrect future action (Table 1).3

Speeds Time to Next Steps

Reliable and reproducible, this assay is designed for routine use with the Sentosa SQ workflow. By integrating genotyping and RAS identification into a single automated workflow, you eliminate running multiple assays and are able to move to the next steps more quickly. This fully automated solution requires less than 2.5 hours of hands-on-time, delivering results from sample to answer in just 2 days. Both Laboratory Information System (LIS) connectivity and system and extraction controls are integrated into the workflow, giving you confidence in the results while removing many user interactions with the system to further streamline the workflow (Figure 1).

This ready-to-use platform can be running your lab in less than two weeks. Vela Diagnostics offers a reagent rental model as an alternative to capital equipment purchase. Please contact your sales representative for more information.
Expert sequence design

The Sentosa® SQ HCV Genotyping Assay employs a multiplexed sequencing design targeting 3 therapeutically important regions of the Hepatitis C Virus genome: NS3, NS5A, and NS5B. This sequencing strategy thus maximizes sequencing reads on the most informative regions of the HCV genome. By targeting the NS5B region of the HCV genome instead of the 5'UTR, typically targeted by traditional HCV genotyping assays, even recombinant strains can be identified. This approach enables correct genotyping of recombinant viruses while simultaneously identifying clinically relevant RASs (Fig. 2). Additionally, this approach overcomes many of the uninterpretable results seen with LiPA (6.7% uninterpretable results with LiPA) by providing direct sequencing results.

Furthermore, this assay design enables you to identify subtypes beyond 1a and 1b, delivering subtypes for 70 of the subtypes for Hepatitis C with accuracy. This advances your research, allowing you to discover potential new relationships between subtypes and therapeutics under investigation. Additionally, DNA contigs are readily available for further sequence analysis enabling assessment of additional mutations specific to the specimen under investigation. This may prove useful for further bioinformatics analyses in conjunction with monitoring resistance to novel drug treatments in your research.

### Table 1: Genotyping accuracy with NGS compared with LiPA analysis.

150 samples were analyzed using both next-generation sequencing (Sentosa® SQ HCV Genotyping Assay) and line probe assay analysis (VERSANT® HCV Genotype 2.0 Assay). These samples were randomly selected archived serum or plasma samples from 143 Asian and 7 African patients with chronic HCV infection, viral loads ranging from 5.50x10² to 1.04x10⁸ IU/mL (median 6.10x10⁶). The genotype (GT) distribution was as follows: 11 GT1a, 14 GT1b, 12 GT2, 58 GT3, 9 GT4, 7 GT5, and 39 GT6. In 16/150 (11%) of samples, discordant results between the two methods were obtained. Confirmation testing by Sanger sequencing indicated that the ability to discriminate at the major GT level was 89.3% (95%CI: 83.4 – 93.3) for LiPA and 100% (95%CI: 97.5-100) for Sentosa NGS. Correct GT subtype calls were found to be 89% for LiPA and 100% for NGS. Among the 16 discordant samples, 8 GT6 were wrongly classified as GT1b with LiPA, 6 GT3 as GT4, and another 2 GT3 as GT6.

### Figure 1: Single, automated NGS workflow for HCV Genotyping & RAS analysis.

Workflow diagram details the steps involved from sample through analysis using the Sentosa® SQ HCV Genotyping Assay. This workflow requires less than 2.5 hours of hands on time and delivers results in 2 days.

### Figure 2: Schematic shows recombinant HCV strains identified to date.

This depicts recombinant sites for the identified species, demonstrating that in these cases the recombination occurs prior to NS3, leading to accurate genotyping with the Sentosa SQ HCV Genotyping Assay while still covering all 3 drug target regions for RAS testing.
Hepatitis C Virus RNA

Target Region Detection

<table>
<thead>
<tr>
<th>Codon 1 to 267</th>
<th>Codon 14 to 201</th>
<th>Codon 346 to 559</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAV Detection for GT 1a &amp; 1b</td>
<td>RAV Detection for GT 1a &amp; 1b</td>
<td>RAV Detection for GT 1a &amp; 1b and Detection for GT 3, 4, 5, 6</td>
</tr>
</tbody>
</table>

RAV Detection for GT 1a & 1b and Detection for GT 1a, 2, 3, 4, 5, 6

Sentosa® SQ HCV Genotyping Assay Specifications

- **Analytical sensitivity**
  - >1,000 HCV IU/mL for genotypes 1a, 1b, 2, 3 & 4
  - >2,000 HCV IU/mL for genotypes 5 & 6

- **Analytical specificity**
  - No cross-reactivity with HAV, HBV, HIV, CMV, EBV, BKV, Dengue virus or genomic DNA

- **Reproducibility**
  - 99.2% (95% confidence interval: 97.20%-99.79%)

- **Controls**
  - 1 system control, 1 extraction control

- **Amplicons targeted**
  - NS5B, NS3, & NS5A;

- **Automated result calling**
  - GT 1 through 6 with RAS reporting for GT1a, 1b & 3. Sequence information for NS5B, NS3 & NS5A accessible in BAM files.

- **Coverage/target**
  - >200x for genotyping, >500x for RAS calling

- **Sample types supported**
  - Plasma & serum

- **Sample input required**
  - 530 uL

- **Sample throughput**
  - 15 samples/run, 80 samples/week

- **Time to results**
  - 2 days

- **Hands on time**
  - Less than 2.5 hours

For more information, visit VelaDX.com/HCV

References


3. Data from “Next Generation Sequencing (NGS) for HCV genotyping and optional identification of resistance-associated variants”. Presented at AASLD Annual Meeting 2015 (Kok Siong Poon, Evelyn S. Koay, Cui Wen Chua, Mui Joo Khoo, **Zhang Rui, **Elian Rakhmanaliev, **Wen Huang and **Gerd Michel

* Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Hospital, Singapore; Department of Pathology, Na=onal University of Singapore, Singapore;**Vela Research Pte Ltd., Singapore)


Sentosa® SQ HCV Genotyping Assay Specifications

- Analytical sensitivity: >1,000 HCV IU/mL for genotypes 1a, 1b, 2, 3 & 4
- Analytical specificity: No cross-reactivity with HAV, HBV, HIV, CMV, EBV, BKV, Dengue virus or genomic DNA
- Reproducibility: 99.2% (95% confidence interval: 97.20%-99.79%)
- Controls: 1 system control, 1 extraction control
- Amplicons targeted: NS5B, NS3, & NS5A;
- Automated result calling: GT 1 through 6 with RAS reporting for GT1a, 1b & 3. Sequence information for NS5B, NS3 & NS5A accessible in BAM files.
- Coverage/target: >200x for genotyping, >500x for RAS calling
- Sample types supported: Plasma & serum
- Sample input required: 530 uL
- Sample throughput: 15 samples/run, 80 samples/week
- Time to results: 2 days
- Hands on time: Less than 2.5 hours

Figure 3: Illustration of Hepatitis C Virus RNA genes and regions targeted by the Sentosa SQ HCV Genotyping Assay design. Major RASs are identified and reported through the Sentosa SQ Reporter Software in accordance with the guidelines as well as targeted gene regions corresponding to the genotyping information.

Ordering Information

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Pack Size</th>
<th>Item Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentosa® SQ HCV Genotyping Assay</td>
<td>4x16 tests</td>
<td>690019</td>
</tr>
<tr>
<td>Sentosa® ST Template Kit</td>
<td>8 runs</td>
<td>690007</td>
</tr>
<tr>
<td>Sentosa® SQ Sequencing Kit</td>
<td>8 runs</td>
<td>690005</td>
</tr>
<tr>
<td>Sentosa® SQ 318 Chip Kit</td>
<td>8 runs</td>
<td>300301</td>
</tr>
<tr>
<td>Sentosa® SX Virus Total Nucleic Acid Plus II Kit</td>
<td>4x16 tests</td>
<td>300352</td>
</tr>
<tr>
<td>Sentosa® SX101</td>
<td>1</td>
<td>400089</td>
</tr>
<tr>
<td>Sentosa® NGS Starter Kit</td>
<td>1</td>
<td>400105</td>
</tr>
<tr>
<td>Sentosa® SQ301 (120V) with SQ301 Minicentrifuge</td>
<td>1</td>
<td>690026</td>
</tr>
<tr>
<td>Sentosa® ST401</td>
<td>1</td>
<td>690027</td>
</tr>
<tr>
<td>Sentosa® Link</td>
<td>1</td>
<td>400045</td>
</tr>
<tr>
<td>Sentosa® SQ Reporter (software, server and perpetual license)</td>
<td>1</td>
<td>690014</td>
</tr>
</tbody>
</table>

For more information, kindly contact your Vela Diagnostics representative. All rights reserved. Vela is a trademark of Vela Diagnostics Holding Pte Ltd. Sentosa® is a registered trademark of Vela Diagnostics Holding Pte Ltd in several markets including the US and the European Union.